Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB
Neuroscientific Biopharmaceuticals — ISCT ANZ 2026
12 slides from Neuroscientific Biopharmaceuticals's conference presentation, Jul 21, 2026
Slide 1: StemSmart MSC: GMP-manufactured, patented mesenchymal stromal cell platform
ASX:NSB For personal use only StemSmart™ MSC A GMP-manufactured, patented mesenchymal stromal cell platform for immune-mediated inflammatory disease Catherine Cole | Chief Medical Officer ISCT | ANZ 2026
Slide 2: Mesenchymal Stem Cells (MSC)
Mesenchymal Stem Cells (MSC) For personal use only Multipotent non-engrafting cells with expansion capacity and multi-lineage differentiation.1 Adherent, fibroblast-like cells found in bone marrow, adipose tissue, placenta, umbilical cord and other tissue sources. Low immunogenicity and do not requir
Slide 3: Cellular Targets of MSC
Cellular Targets of MSC For personal use only Regulating inflammation across innate and adaptive immunity Innate Immunity Effector T-cell Adaptive Immunity Natural Killer cell Inhibits T-cell proliferation Inhibits NK activation Promotes anti-inflammatory cytokine secretion Inhibits NK proliferation I
Slide 4: Roles of MSC
Roles of MSC For personal use only Immune/Inflammatory Diseases Immunosuppression and immunoregulation: Graft versus Host Disease (GvHD) following allogeneic hematopoietic stem cell transplantation with promising outcomes.1 Immunomodulation: preliminary clinical trials2 : ● Crohn’s Disease ● Systemic
Slide 5: Introducing StemSmart
Introducing StemSmart™ For personal use only Purpose-built Mesenchymal Stem Cell (MSC) therapy for patients with limited options¹ Designed for Home to inflammation sites and modulate severe inflammation the immune response Activated MSC Optimised to enhance therapeutic activity Targets Developed for p
Slide 6: Securing the StemSmart Manufacturing Process
Securing the StemSmart™ Manufacturing Process For personal use only From bone marrow aspirate collection to culture expansion, harvest and cyropreservation Mesenchymal Stromal Cell Culture Expansion Cryopreservation, Final Harvest & Formulation 1 2 3 4 5 Bone Marrow Aspirate Seeding and culture of H
Slide 7: Crohn's Disease
Crohn’s Disease For personal use only A progressive disease with significant patient burden, economic cost and limited durable treatment options 70,000+ 1,000+ 15–40yrs $3.1B+ $361M Australians affected new cases annually most commonly affected annual economic cost productivity loss Progressive compl
Slide 8: Significant Clinical Response
Significant Clinical Response For personal use only Demonstrated in Previous Clinical Trial with Refractory Crohn’s Patients: Forbes et al Royal Perth Hospital. 78% 44% demonstrated achieved clinical response*¹ remission**¹ StemSmart ™ *defined as reduction in Crohn’s disease **defined as reduction in
Slide 9: Special Access Program – StemSmart
Special Access Program1,2 – StemSmart™ For personal use only For Patients with Fistulising Crohn’s Disease – a significant unmet medical need 4 /5 patients achieved a clinical response3,4 (≥50% fistula closure or discharge reduction) What does this mean for NSB? Special Access Scheme Fistulising Crohn
Slide 10: Clinical Program
Clinical Program For personal use only Preparations in progress for Phase 2 Clinical Trials Fistulising Crohn's Disease Refractory Crohn's Disease Phase 2 clinical trial in Australia only Phase 2 clinical trial in US & Australia Australian TGA Clinical Trial Notification pathway US FDA Investigationa
Slide 11: Future StemSmart Platform Opportunities
Future StemSmart™ Platform Opportunities For personal use only Expanding into high-inflammation conditions where current treatment options remain limited Renal transplantation Lung transplantation / Supporting immune chronic lung disease tolerance and reducing Potential application in transplant-rela
Slide 12: Contact
ASX:NSB For personal use only Contact Catherine Cole | Chief Medical Officer NeuroScientific Biopharmaceuticals Ltd ir@neuroscientific.com